Form 8-K - Current report:
SEC Accession No. 0001628280-21-021748
Filing Date
2021-11-04
Accepted
2021-11-04 16:01:37
Documents
15
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crdf-20211104.htm   iXBRL 8-K 38921
2 EX-99.1 crdf11421-q32021pr.htm EX-99.1 126771
6 cardiff_logoxrgbxtm.jpg GRAPHIC 176318
7 crdf-20211104_g1.jpg GRAPHIC 176318
  Complete submission text file 0001628280-21-021748.txt   976527

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT crdf-20211104.xsd EX-101.SCH 1935
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT crdf-20211104_lab.xml EX-101.LAB 23007
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT crdf-20211104_pre.xml EX-101.PRE 12131
8 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20211104_htm.xml XML 10069
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35558 | Film No.: 211379798
SIC: 2836 Biological Products, (No Diagnostic Substances)